CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-24). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1881 · Search date 2026-07-24 · Methodology v0.6

Mesh-reinforced hernia repair,
does it really help with Reduced inguinal or femoral hernia recurrence versus non-mesh tissue repair?

30-Second Summary
A
Evidence Grade A · 84 · Safety caution
Mesh reinforcement meaningfully reduces recurrence compared with tissue repair alone
Seroma increased across 14 trials, with 46/1,373 versus 25/1,267 events, RR 1.63 (95% CI 1.03 to 2.59), I-squared 0%. Chronic or postoperative pain was reported in 22 trials and 4,999 participants but could not be pooled because scales and time points differed.
What the
research shows
Mesh repair earns A with 84 points because it reduces groin-hernia recurrence versus non-mesh repair. Across 21 trials and 5,575 participants, recurrence was 52/2,834 versus 110/2,741, RR 0.46 (95% CI 0.26 to 0.80), I-squared 44%, with an NNTB of about 46.
What the
ads claim
Lower recurrence does not mean that mesh is complication-free or best for every patient. Chronic pain, seroma, infection, technique, and patient preference remain separate decisions.
*

Useful facts when choosing a product

  • The review included 25 trials and 6,293 participants, while recurrence analysis used 21 trials and 5,575 participants.
  • One trial had manufacturer support, one had university and hospital support, and 23 did not report funding.
  • Recurrence definitions varied and median follow-up was not reported.
Gap Measurement · Verdict 1881 · A 84
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Lockhart et al. 2018 included 25 randomized trials and 6,293 participants. Recurrence in 21 trials and 5,575 participants had RR 0.46 (95% CI 0.26 to 0.80), I-squared 44%, and an NNTB of about 46, but definitions varied and median follow-up was unreported; only a maximum of five years was stated. Chronic or postoperative pain was reported by 22 trials and 4,999 participants but could not be pooled because scales and time points differed.

02

Why this is classified as A (84)

A large reduction in actual recurrence was replicated across randomized trials, but mostly unreported funding, varying definitions, and unreported median follow-up keep it at A with 84 points rather than the top score.

Counterpoint. Seroma increased significantly, while chronic or postoperative pain could not be pooled because scales and time points differed.

Rejudgment record. Cross-check applied — Replicated reduction in actual recurrence, limited by mostly unreported funding, varying recurrence definitions, and unreported median follow-up

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR2Independently replicated across trials
IndependenceI1Mixed funding sources
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (A).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduced inguinal or femoral hernia recurrenceAThe pooled RR across 21 trials was 0.46.
Long-term recurrence reduction after open mesh repairAThe individual-data meta-analysis found a 50% to 75% reduction.
Faster return to normal activitiesBTen trials found a mean 2.87-day improvement, with high heterogeneity.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Lockhart K et al. 2018Cochrane systematic review and meta-analysis of randomized trials5,575One manufacturer-supported trial, one university- and hospital-supported trial, and 23 with funding unreportedPrimary outcome of hernia recurrence52 of 2,834 versus 110 of 2,741; RR 0.46 (95% CI 0.26 to 0.80), primary outcome successfulDecisive replicated evidence
Grant AM, EU Hernia Trialists Collaboration. 2002Individual-participant-data meta-analysis5,016Public EU BIOMED II funding; Aberdeen research units core-funded by the Scottish ExecutiveClinical recurrence and persistent painMesh reduced recurrence risk by 50% to 75%, supporting the primary conclusionIndependent publicly funded replication
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-24).

Lockhart K, Dunn D, Teo S, et al. Mesh versus non-mesh for inguinal and femoral hernia repair. Cochrane Database Syst Rev. 2018;2018(9):CD011517. DOI: 10.1002/14651858.CD011517.pub2.
checked
Grant AM; EU Hernia Trialists Collaboration. Open mesh versus non-mesh repair of groin hernia: meta-analysis of randomised trials based on individual patient data. Hernia. 2002;6(3):130-136. PMID: 12209302. DOI: 10.1007/s10029-002-0073-1.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none

Cite this verdict

Mesh-reinforced hernia repair x prevention of recurrence Evidence Grade A card
[Chamgap] Mesh-reinforced hernia repair x prevention of recurrence — Evidence Grade A·84. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/general/mesh-repair-groin-hernia-recurrence/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.